Bahrain Oncology Centre offers gene therapy CASGEVY for sickle cell disease and thalassemia, following bone marrow transplant accreditation.
Bahrain Oncology Centre (BOC) becomes one of the first globally to offer ground-breaking gene therapy CASGEVY (exa-cel) for sickle cell disease (SCD) and transfusion dependent thalassemia (TDT). This follows BOC's successful accreditation for bone marrow transplant and cell therapy services. A collaborative effort between the Ministry of Health, Royal Medical Services, Government Hospitals, and the National Health Regulatory Authority.
May 22, 2024
4 Articles